Steba Biotech

Company snapshot

Photodynamic therapy for prostate cancer Photodynamic Therapy (PDT) is a sophisticated and powerful technique that can be used for cancer treatment, for example prostate cancer. It is a technique that enables the destruction of a target tissue via the administration of an inactive, light-sensitive agent (a "photosensitizer") and the local application of light, in the presence of oxygen. The photos

• 1 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Steba Biotech. Not investment advice.

• What is Steba Biotech?

  STEBA Biotech is a biotech organization headquartered in EU. Primary therapeutic focus areas include Low Grade Upper Tract Urothelial Cancer. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.

• Is Steba Biotech publicly traded?

  Steba Biotech appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Steba Biotech develop or market?

  We link 4 drug profile(s) where Steba Biotech is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/steba-biotech-s-a#company-drugs.

• What are the latest developments for Steba Biotech?

  In the last 12 months our linked public records show 1 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Steba Biotech focus on?

  Steba Biotech focuses on Low Grade Upper Tract Urothelial Cancer based on our analysis of their pipeline programs and drug development activities.